New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
17:56 EDTCVS, MDTRelational Investors reports decreased stakes in CVS Caremark, Medtronic
News For CVS;MDT From The Last 14 Days
Check below for free stories on CVS;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
16:24 EDTMDTOn The Fly: Closing Wrap
Subscribe for More Information
12:26 EDTMDTOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTMDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Subscribe for More Information
10:02 EDTMDTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:00 EDTMDTMedtronic falls 5.4%
Medtronic is down 5.4%, or $3.20, to $56.00
08:59 EDTMDTOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTMDTEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:22 EDTMDTMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTMDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
April 13, 2014
15:10 EDTMDTMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTMDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
11:23 EDTCVSRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
April 8, 2014
13:24 EDTCVSCVS confirms final SEC settlement, says will not be required to restate earnings
Subscribe for More Information
13:08 EDTCVSCVS Caremark pays $20M to settle SEC accounting charges
The SEC announced that it charged CVS Caremark "with misleading investors about significant financial setbacks and using improper accounting that artificially boosted its financial performance." CVS has agreed to pay $20M to settle the charges, the agency said. Reference Link
07:26 EDTMDTElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
07:24 EDTCVSCVS Caremark price target raised to $84-$89 from $75-$80 at Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use